Literature DB >> 27644901

The rationale of combined radiotherapy and chemotherapy - Joint action of Castor and Pollux.

Thomas B Brunner1.   

Abstract

This article aims to review the rationale behind the combination of radiotherapy and chemotherapy. Theoretical concepts describing the principles of the joint effects of chemoradiotherapy are reviewed. Preclinical and clinical evidence are collected and summarised demonstrating the co-operation between the two modalities which form the mainstay of the treatment of most solid tumours. Initially, the evolution of chemoradiotherapy was mostly empirically driven which is true for both, the early studies and the experimental investigations, rather than relying on scientific rationale. To date, the revised Steel's model proposes five mechanisms, spatial cooperation, cytotoxic enhancement, biological co-operation, temporary modulation and normal tissue protection to describe the interaction between radiotherapy and chemotherapy. Chemoradiotherapy has become the standard modality for most patients with locally advanced solid tumours due to better control of loco-regional disease and prolonged survival. Gradually, molecular prediction of efficacy is integrated such as MGMT status for combining temozolomide with radiotherapy in glioblastoma. As molecular targeted drugs are ready to be taken into triple combinations with chemoradiotherapy it is crucial to have a good understanding of the mechanisms of chemoradiotherapy for the rational development of future combinations.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Combined modalities; Drug-radiotherapy interaction; Radiotherapy

Mesh:

Year:  2016        PMID: 27644901     DOI: 10.1016/j.bpg.2016.07.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  4 in total

1.  pH- and Ultrasound-Responsive Paclitaxel-Loaded Carboxymethyl Chitosan Nanodroplets for Combined Imaging and Synergistic Chemoradiotherapy.

Authors:  Mengmeng Shang; Xiao Sun; Lu Guo; Dandan Shi; Ping Liang; Dong Meng; Xiaoying Zhou; Xinxin Liu; Yading Zhao; Jie Li
Journal:  Int J Nanomedicine       Date:  2020-01-24

2.  New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective.

Authors:  Simona Sestito; Massimiliano Runfola; Marco Tonelli; Grazia Chiellini; Simona Rapposelli
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

3.  Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.

Authors:  Shuraila F Zerp; Zainab Bibi; Inge Verbrugge; Emile E Voest; Marcel Verheij
Journal:  Clin Transl Radiat Oncol       Date:  2020-06-09

4.  A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus.

Authors:  Yunpeng Zhao; Yongqiang Wang; Lei Shan; Chuanliang Peng; Wenhao Zhang; Xiaogang Zhao
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.